Kopran receives UK MHRA approval for Khopoli facility

Kopran Ltd has informed BSE that the UK, Medicines and Healthcare products Regulatory Agency (UK MHRA) has granted the certificate of compliance with principles and guidelines of good manufacturing practice (GMP) for the finished dosage forms facility located at Khalapur, Khopoli (Maharashtra), manufacturing general capsules arid tablets.
 
The approval for this facility will enable Kopran to supply finished dosage forms to the UK and the European market for which necessary marketing tie-ups are being entered into.
 
The facility also has approvals from regulatory authorities of several countries all over the world including the Medicines Control Council (MCC) of South Africa and the Therapeutic Goods Administration (TGA) of Australia.